Advertisement

Topics

Termination of Business Transfer Discussion with Kaketsuken

11:00 EDT 19 Oct 2016 | Astellas Pharma Inc.

Tokyo, October 19, 2016  - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas” ) today announced that Astellas has terminated the discussion with the Chemo-Sero-Therapeutic Research Institute (“Kaketsuken”) with respect to the potential transfer of business.

Astellas has discussed with Kaketsuken with respect to the potential transfer of business of Kaketsuken to Astellas, but taking into the current situation and various factors, Astellas has decided to terminate the discussion with Kaketsuken.

It will not affect the existing agreement with Kaketsuken and associated business.

Astellas will continue making efforts on providing appropriate information and stable supply as a distributor of products of Kaketsuken.

Original Article: Termination of Business Transfer Discussion with Kaketsuken

NEXT ARTICLE

More From BioPortfolio on "Termination of Business Transfer Discussion with Kaketsuken"

Quick Search
Advertisement
 

Relevant Topic

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...